Necrotic skin eruptions in cancer patients on immune checkpoint inhibitors (ICIs) should trigger immediate evaluation for severe myositis, according to a paper published online October 7, 2026 in the Journal of the American Academy of Dermatology.

The report, authored by Wenxi Li, Xinzhi Xu, Yuchen Shen, Kexin Sun, Xue Han, and Ji Yang, frames cutaneous necrosis as a clinical sentinel in patients who develop dermatomyositis during checkpoint blockade.

What does the paper change for clinicians?

The title itself — Necrotic eruptions indicate severe myositis in immune checkpoint inhibitor-associated dermatomyositis — repositions a rare cutaneous finding as a diagnostic priority.

Classic dermatomyositis features such as heliotrope rash, Gottron papules, shawl sign, and nailfold capillary changes are widely recognized immune-related adverse events (irAEs) of anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 (ipilimumab) therapy. Necrotic lesions are not.

The authors argue that, in the ICI-treated patient, necrotic skin should push the differential away from a purely cutaneous irAE and toward a systemic syndrome requiring urgent muscle workup.

Why is this distinction urgent?

ICI-associated myositis runs a different course from idiopathic dermatomyositis. Published case literature describes:

• Rapid proximal weakness
• Bulbar involvement with dysphagia and dysphonia
• Respiratory muscle compromise
• Concurrent myocarditis
• Overlap with myasthenia-like presentations

The recent characterization of an ICI-induced overlap myositis/myasthenia spectrum carries mortality rates that justify aggressive intervention: high-dose corticosteroids, holding or stopping the offending agent, and escalation to intravenous immunoglobulin, plasma exchange, or targeted immunosuppression.

What should dermatologists do at the bedside?

When a patient on checkpoint blockade presents with a new dermatomyositis-like rash, the authors urge adding necrotic lesions to the list of findings that change management. Practical steps include:

• Serum creatine kinase (CK) and aldolase
• Transaminases and troponin screening
• Electromyography when weakness is reported
• MRI or muscle biopsy for confirmation in equivocal cases
• Multidisciplinary oncology, neurology, and rheumatology input

How does this fit the broader irAE picture?

The paper reflects an expanding role for dermatologists in active cancer care. Skin irAEs — bullous pemphigoid, lichenoid eruptions with mucosal disease, and Stevens-Johnson syndrome-like reactions — already alter oncologic decision-making. Necrotic eruptions may belong on that list.

As checkpoint inhibitors move into earlier lines of therapy and across more tumor types, the at-risk population continues to grow. Sharper clinical triage at the cutaneous end of the irAE spectrum can shorten the time to life-saving immunosuppression.

If subsequent cohorts confirm the authors' observations, the paper is positioned to inform upcoming revisions of NCCN and ESMO irAE guidelines, where cutaneous phenotypes of severe systemic irAEs remain incompletely codified.